“genfit” Archives

in
Entry Author Date Location
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More 10/02/20 National
Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries 10/01/20 Europe
Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More 07/24/20 National
FDA Lifts CymaBay Drug Hold, Tests to Resume in Rare Liver Disease PBC 07/23/20 San Francisco
3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments 07/13/20 National
FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data 06/29/20 New York
Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More 05/15/20 National
Genfit Contender in Heated NASH Drug Race Fails in Phase 3 Study 05/11/20 National
Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data 04/10/20 National
NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data 02/24/20 San Francisco
Looking to Level Up in NASH, Novo Nordisk Licenses Ube Drug Candidate 11/08/19 National
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone 09/06/19 National
Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More 06/28/19 National
Conatus to Slash Staff, Consider Sale After NASH Trial Failures 06/25/19 San Diego
CymaBay Therapeutics Stumbles in NASH Race, Shares Fall 06/11/19 San Francisco
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More 03/29/19 National
Bio Roundup: Pharma in DC, Bristol-Cel in Trouble, Roche Gets A Spark 03/01/19 National
With New Data, Intercept On Track for First-Ever Approved NASH Drug 02/19/19 New York
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
15 For ’18: Key Clinical Data to Watch For Next Year (Part 1) 12/04/17 National
Tobira Fails Main Goal in NASH Study, But Forges Ahead To Next Trial 07/25/16 San Francisco
Intercept’s Liver Drug Wins FDA Approval To Treat Rare Disease 05/28/16 New York
As Rivals Make News, Intercept Heads To Daylong Hearing For Liver Drug 04/06/16 New York
East Coast Biotech Roundup: Hemophilia, Levin, Vertex, Semma & More 03/27/15 Boston
With $43M, Nimbus Sheds “Discovery” Tag, Heads to First Clinical Test 03/18/15 Boston
Page 1 of 1